# An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)

> **NCT01836133** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 70 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib 150 mg

## Key facts

- **NCT ID:** NCT01836133
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2017-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01836133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01836133, "An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01836133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*